C07C69/732

Polymeric biomaterials derived from phenolic monomers and their medical uses

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

Polymeric biomaterials derived from phenolic monomers and their medical uses

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile

Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.

Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile

Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.

USE OF SUBSTITUTED CINNAMIC ACID ESTERS AS STABILISERS FOR ORGANIC MATERIALS, STABILISED ORGANIC MATERIAL, METHOD FOR STABILISING ORGANIC MATERIALS AND SPECIFIC CINNAMIC ACID ESTERS

The present invention relates to the use of specific cinnamic acid esters as stabilizers of organic materials, in particular against oxidative, thermal and/or actinic degradation. The invention also relates to a corresponding stabilized organic material. The invention further relates to a method for stabilizing organic materials, in which specific cinnamic acid esters are incorporated into the organic material. According to the invention, specific new cinnamic acid esters are also disclosed.

POLYMERIC FATTY ACID COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID-BASED SUBSTRATES, ESPECIALLY HAIR

The present invention is directed at mono-, di- or polyquaternary ammonium compounds of the formula (I) wherein x is 1 to 50, and F can be the same or different and is represented by the general formula (II) wherein at least one of the optionally substituted and optionally functional-group-containing hydrocarbon radicals R.sup.1, R.sup.2, R.sup.3, R.sup.4 or R.sup.5 contains at least one estolide moiety comprising two or more ester or amide moieties. The invention also relates to a process for the synthesis of such compounds, the use of the compounds in cosmetic formulations for skin and hair care, cosmetic compositions for the treatment of fibers, and compositions containing one or more of the compounds for the treatment of hair.

##STR00001##

CALIXARENE COMPOUND, CURABLE COMPOSITION AND CURED PRODUCT

Provided is a calixarene compound represented by structural formula (1). In structural formula (1), R.sup.1 and R.sup.2 each independently represent a structural moiety (A) having a functional group (I), a structural moiety (B) having a functional group (II) having a carbon-carbon unsaturated bond (excluding maleate groups), a structural moiety (C) having both the functional group (I) and the functional group (II), a monovalent organic group (D) that has 1 to 20 carbon atoms and is other than the structural moieties (A), (B) and (C), or a hydrogen atom (E). At least one of a plurality of R.sup.2s is the structural moiety (A), the structural moiety (B), the structural moiety (C), or the organic group (D).

##STR00001##

CALIXARENE COMPOUND, CURABLE COMPOSITION AND CURED PRODUCT

Provided is a calixarene compound represented by structural formula (1). In structural formula (1), R.sup.1 and R.sup.2 each independently represent a structural moiety (A) having a functional group (I), a structural moiety (B) having a functional group (II) having a carbon-carbon unsaturated bond (excluding maleate groups), a structural moiety (C) having both the functional group (I) and the functional group (II), a monovalent organic group (D) that has 1 to 20 carbon atoms and is other than the structural moieties (A), (B) and (C), or a hydrogen atom (E). At least one of a plurality of R.sup.2s is the structural moiety (A), the structural moiety (B), the structural moiety (C), or the organic group (D).

##STR00001##

PROCESS FOR PREPARING CYANOACETATES

This invention relates to a process for producing cyanoacetates involving contacting a salt of an alkyl, alkenyl, alkynyl or aryl formyl acetate with a hydroxyl amine acid under appropriate conditions and for a time sufficient to yield a cyanoacetate.

PROCESS FOR PREPARING CYANOACETATES

This invention relates to a process for producing cyanoacetates involving contacting a salt of an alkyl, alkenyl, alkynyl or aryl formyl acetate with a hydroxyl amine acid under appropriate conditions and for a time sufficient to yield a cyanoacetate.